Treatment of Prostatic Cancer by Monthly Injections of An LHRH-Analogue Depot

References

• Ahmed S. R., Grant J. B. F., Shalet S M., et al. A new hormonal therapy for prostatic cancer: Long-term clinical and hormonal response. Br. J. Urol. 1986; 58: 534
   PubMedGoogle Scholar
• Ahmed S. R., Grant J. B. F., Shalet S M., et al. Preliminary report on use of depot formulation of LHRH-analogue ICI 118630(Zoladex) in patients with prostatic cancer. Br. Med. J. 1985; 290: 18
   Google Scholar
• Bambino T. A., Schreiber J. K., Hsueh A. J. W. GnRH and its agonist inhibit testicular LH receptors and steroidogenesis in immature and adult hypophysectomised rats. Endocrinol. 1980; 107: 908
   PubMed Web of Science ®Google Scholar
• Bhasin S., Heber D., Steiner B. S., Handelsman D. J., Swerdloff R. S. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long-term combined treatment with GnRH agonist and androgen. J. Clin. Endocrinol. Metab. 1985; 60: 998
   PubMed Web of Science ®Google Scholar
• Chisholm C. D., Beynon L. L. The response of the malignant prostate to endocrine treatment. The endocrinology of prostate tumours, Ghanadian, Lancaster 1982; 241
   Google Scholar
• Clayton R. N., Huhtaniemi I. T. Absence of gonadotrophin-releasing hormone receptors in human gonadal tissue. Nature 1982; 299: 56
   PubMed Web of Science ®Google Scholar
• Clayton R N., Katikineni M., Chan V., Defau M. L., Catt K. J. Direct inhibition of testicular function by gonadotropin-releasing hormone: Mediation by specific gonadotropin-releasing hormone receptors in interstitial cells. Proc. Natl. Acad. Sci. USA 1980; 77: 4459
   PubMed Web of Science ®Google Scholar
• Deghenghi R., Misset J. L. Disease flare induced by luteinizing hormone releasing hormone analogues in cancer patients. Lancet I 1984; 1302: 9, Eaton A. C. and McGuire N.: Cyproterone acetate in treatment of postorchidectomy hot flushes. Double-blind crossover trial. Lancet II (1983), 1336.
   Google Scholar
• Henriksson P., Edhag O. Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects. Br. Med. J. 1986; 293: 413
   PubMedGoogle Scholar
• Huggins C., Hodges C. V. Studies on prostatic cancer. II. The effects of castration, of estrogen and of androgen injection on the serum phosphatasis in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293
   Google Scholar
• Huhtaniemi I., Nikula H., Ranikko S. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analogue: Acute and long term effects on endocrine functions of testicular tissue. J. Clin. Endocrinol. Metab. 1985; 61: 698
   PubMed Web of Science ®Google Scholar
• Mathé G., Schally A. V., Comaru Schally A M., et al. Phase II trial with D-TRP-6-LH-RH in prostatic carcinoma: Comparison with other hormonal agents. Prostate 1986; 9: 327
   PubMedGoogle Scholar
• Parmar H., Edwards L., Phillips R. H., Allen L., Lightman S. L. Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br. J. Urol. 1987; 59: 248
   PubMedGoogle Scholar
• Parmar H., Edwards L., Phillips R. H., Allen L., Lightman S L., Lightman S. L., Allan L, et al. Randomized controlled study of orchidectomy vs. long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet II 1985; 1201
   PubMedGoogle Scholar
• Petersson F., Hammar M., Mathson K., Hjertberg H., Varenhorst E. Influence of continuous luteinizing hormone-releasing hormone agonist treatment on steroidogenic enzymes in the human testis. Scand. J. Nephrol. Urol. 1987; 21: 267
   PubMed Web of Science ®Google Scholar
• Present C. A., Soloway M. S., Klioze S S., et al. Buserelin as primary therapy in advanced prostatic carcinoma. Cancer 1985; 56: 2416
   PubMedGoogle Scholar
• Rajfer J., Sikka S. C., Swerdloff R. W. Lack of direct effect of gonadotropin hormone releasing hormone agonist on human testicular steroidogenesis. J. Clin. Endocrinol. Metab. 1987; 64: 62
   PubMedGoogle Scholar
• Robinson M. R., Denis L., Mahler C., Walker K., Stitch R., Lunglmayer G. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections. Eur. J. Surg. Oncol. 1985; 11: 159
   PubMedGoogle Scholar
• Tolis G., Ackman D., Stellos A, et al. Tumour growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc. Natl. Acad. Sci. USA 1982; 79: 1658
   PubMed Web of Science ®Google Scholar
• Van Gangh P. J., Opsomer R. J. Treatment of advanced carcinoma of the prostate with a depot luteinizing hormone-releasing hormone analogue (ICI-118630). J Urol. 1987; 137: 61
   PubMedGoogle Scholar
• Varenhorst E., Svensson M., Hjertberg H., Malmqvist E. Antithrombin III concentration as a predictor of thrombosis. Br. Med. J. 1986; 292: 935
   PubMedGoogle Scholar
• Varenhorst E., Svensson M., Hjertberg H, Wallentin L., Risberg B. Clotting predisposition in carcinoma of the prostate. Letter to the editor. J. Urol. 1986; 126: 419
   Google Scholar
• Winfield H., Trachtenberg J. A comparison of powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer. J. Urol. 1984; 131: 1107
   PubMedGoogle Scholar